Kaposi's sarcoma epidemiology and demographics

Jump to: navigation, search

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma epidemiology and demographics

CDC on Kaposi's sarcoma epidemiology and demographics

Kaposi's sarcoma epidemiology and demographics in the news

Blogs on Kaposi's sarcoma epidemiology and demographics

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]Amandeep Singh M.D.[3]

Overview

In the United States, the age-adjusted prevalence of Kaposi sarcoma is 8.1 per 100,000. The age-adjusted incidence of Kaposi sarcoma was 0.64 per 100,000 persons in the United States in 2011. Male are more commonly affected by Kaposi's sarcoma than female. The male to female ratio is approximately 10-15:1.

Epidemiology and Demographics

Incidence

  • In 2011, the age-adjusted incidence of Kaposi sarcoma was 0.64 per 100,000 persons in the United States.[1]
  • Shown below is an image depicting the incidence of Kaposi sarcoma versus all types of cancers in the United States from 1975 to 2011.

Incidence of Kaposi sarcoma versus all types of cancers in the United States from 1975 to 2011

Prevalence

  • In the United States, the age-adjusted prevalence of Kaposi sarcoma is 8.1 per 100,000 in 2011.[1]

Age

  • AIDS-related Kaposi sarcoma usually occurs in young to middle aged patients aged 20-54 years.[2]
  • Classic Kaposi sarcoma generally seen in patients aged 50-70 years.[3]
  • African Kaposi sarcoma occurs in younger age around 35-40 years old.[4]

Gender

  • AIDS-related Kaposi sarcoma usually occurs in homosexual males, bisexual men, and in the female sexual partners of bisexual men.[4][5][6]
  • African Kaposi sarcoma seen in heterosexual men and women equally.
  • Male are more commonly affected by Kaposi's sarcoma than female. The male to female ratio is approximately 10-15:1.[7]

Race

  • Shown below is a table depicting the age-adjusted prevalence of Kaposi sarcoma by race in 2011 in the United States.[1]
All Races White Black Asian/Pacific Islander Hispanic
Age-adjusted prevalence 8.1 per 100,000 8 per 100,000 12.4 per 100,000 2 per 100,000 11.1 per 100,000

References

  1. 1.0 1.1 1.2 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
  2. Luu HN, Amirian ES, Chiao EY, Scheurer ME (December 2014). "Age patterns of Kaposi's sarcoma incidence in a cohort of HIV-infected men". Cancer Med. 3 (6): 1635–43. doi:10.1002/cam4.312. PMC 4298390. PMID 25139791.
  3. Labo N, Miley W, Benson CA, Campbell TB, Whitby D (June 2015). "Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy". AIDS. 29 (10): 1217–25. doi:10.1097/QAD.0000000000000682. PMID 26035321.
  4. 4.0 4.1 Uldrick TS, Whitby D (June 2011). "Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma". Cancer Lett. 305 (2): 150–62. doi:10.1016/j.canlet.2011.02.006. PMID 21377267.
  5. Meditz AL, Borok M, MaWhinney S, Gudza I, Ndemera B, Gwanzura L, Campbell TB (March 2007). "Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe". J. Acquir. Immune Defic. Syndr. 44 (3): 306–8. doi:10.1097/QAI.0b013e31802c83d9. PMID 17146369.
  6. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor M, Stahl R, Spigland I, Kim KS, Zolla-Pazner S (June 1982). "Disseminated Kaposi's sarcoma in homosexual men". Ann. Intern. Med. 96 (6 Pt 1): 693–700. doi:10.7326/0003-4819-96-6-693. PMID 6283973.
  7. Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN (December 2008). "Awareness of Kaposi's sarcoma-associated herpesvirus among men who have sex with men". Sex Transm Dis. 35 (12): 1011–4. doi:10.1097/OLQ.0b013e318182c91f. PMC 2593118. PMID 18665016.

Linked-in.jpg